Department of Obstetrics and Gynecology, Medical University of Bialystok, Bialystok, Poland.
Int J Cancer. 2010 Aug 1;127(3):612-21. doi: 10.1002/ijc.25077.
This study was conducted to evaluate the significance of circulating free DNA (CFDNA), p53 antibody (p53-Ab) and mutations of KRAS gene in the development of endometrial cancer (EC). A total of 109 patients with EC (87 patients with Type I and 22 patients with Type II) took part in this study. KRAS mutations and CFDNA were detected by means of the PCR-RFLP and enriched by the PCR-RFPL method. ELISA was used to analyze plasma p53-Ab. Tissue expression of P53 protein was evaluated immunohistochemically (IHC). The frequency of KRAS mutations was especially high in Grade 2 of Type I EC. CFDNA was frequently detected in patients with early stage of Type II EC at a low level of grade. It is noteworthy that the p53-Ab positive rate increased in the higher grade of Type I tumors. A significant difference in the number of cases with the p53-Ab was found in the advanced stage of Type I tumors. The frequency of KRAS and p53-Ab correlates with tumor stage only in the Type I EC. Plasma CFDNA and p53-Ab offer a chance to develop a procedure for EC Type II diagnosis. The association between tumor cells related to CFDNA and p53-Ab with Type II tumor suggests that it might potentially serve as a marker in predicting the prognosis and offers a possibility to individualize treatment regimen.
本研究旨在评估循环游离 DNA (cfDNA)、p53 抗体 (p53-Ab) 和 KRAS 基因突变在子宫内膜癌 (EC) 发展中的意义。共有 109 例 EC 患者（87 例 I 型和 22 例 II 型）参与了这项研究。通过 PCR-RFLP 检测 KRAS 基因突变，通过 PCR-RFPL 法富集 cfDNA。采用 ELISA 法分析血浆 p53-Ab。采用免疫组化 (IHC) 法评估 P53 蛋白的组织表达。I 型 EC 中 2 级的 KRAS 突变频率特别高。cfDNA 在 II 型 EC 早期、分级较低的患者中经常被检测到。值得注意的是，I 型肿瘤中，p53-Ab 阳性率随肿瘤分级的升高而增加。在 I 型肿瘤的晚期，p53-Ab 阳性的病例数有显著差异。KRAS 和 p53-Ab 的频率仅与 I 型 EC 的肿瘤分期相关。血浆 cfDNA 和 p53-Ab 为 II 型 EC 的诊断提供了一个机会。与 cfDNA 和 p53-Ab 相关的肿瘤细胞与 II 型肿瘤的相关性表明，它可能作为预测预后的标志物，并为个体化治疗方案提供了可能。
